3.05

5.57% -0.18

After Hours: 3.02 -0.03 -0.98%

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is traded at $3.05, with a volume of 8,716. It is down -5.57% in the last 24 hours and up +1.33% over the past month. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Previous Close:

$3.23

Open:

$3.24

24h Volume:

8,716

Relative Volume:

0.33

Market Cap:

$16.58M

Revenue:

Net Income/Loss:

$-14.29M

P/E Ratio:

-0.5515

EPS:

-5.53

Net Cash Flow:

$-12.27M

1W Performance:

-4.54%

1M Performance:

+1.33%

6M Performance:

-25.06%

1Y Performance:

-22.19%

1-Day Range:

$3.02

$3.24

1-Week Range:

$3.02

$3.39

52-Week Range:

$2.1501

$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-463-9385

Address

3805 OLD EASTON ROAD, DOYLESTOWN, MA

Employee

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

APRE's Discussions on Twitter

Compare APRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APRE Aprea Therapeutics Inc	3.05	16.58M	0	-14.29M	-12.27M	-3.99
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

Dec 19, 2024

HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Dec 19, 2024

Dec 13, 2024

Aprea Therapeutics, Inc. Announces Twice Daily Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potential Optimize Clinical Outcomes and Strengthen Clinical Path Forward - Marketscreener.com

Dec 13, 2024

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo

Dec 13, 2024

Dec 11, 2024

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times

Dec 11, 2024

Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan

Dec 11, 2024

Nov 22, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN

Nov 22, 2024

Nov 21, 2024

HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World

Nov 21, 2024

Nov 20, 2024

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024